Pivotal Therapeutics VASCAZEN® - REVEAL Trial Top Line Results to be presented at American Heart Association's Arterioscl...

Pivotal Therapeutics VASCAZEN® - REVEAL Trial Top Line Results to be presented at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions

#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}

Pivotal Therapeutics VASCAZEN® - REVEAL Trial Top Line Results to be presented at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions

PR Newswire

WOODBRIDGE, ON, April 30, 2013

WOODBRIDGE, ON, April 30, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, is pleased to
announce that it will be presenting its top line results from its
recently concluded clinical trial, at the American Heart Association's
Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013
Scientific Sessions to be held in Lake Buena Vista, Florida, USA, May
1-3, 2013.

The poster entitled "Treatment of Omega-3 Nutritional Deficiency
Improves Cardiovascular Disease Risk Factors: Results of the
Randomized, Double-Blind, Placebo-Controlled VASCAZEN^® - REVEAL Trial" will be presented on Friday May 3, 2013 from 8:00am to 10:00am.
Pivotal will be exhibiting in Booth #3 at the ATVB 2013 Scientific
Sessions and will be available to respond to questions or provide
additional information on the poster or its product VASCAZEN^®.

About the Study

The VASCAZEN^®-REVEAL trial is a randomized, double blind, placebo controlled, multi-center
USA based study that enrolled 110 patients. The purpose of the study
was to evaluate the effects of VASCAZEN^® in the correction of Omega-3 deficiency in patients with one or more
risk factors associated with CVD, and to evaluate VASCAZEN^®'s concomitant effects on cardiovascular risk factors including
triglycerides, VLDL cholesterol, LDL cholesterol, and HDL cholesterol
among others. The primary efficacy endpoint was the correction of an
Omega-3 deficiency, and secondary endpoints included positive effects
on lipid profiles, without any adverse events.

About VASCAZEN

VASCAZEN^® is a prescription only Medical Food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular patients.
VASCAZEN^® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents. VASCAZEN^® is the second to market prescription only Omega-3 therapy available in
the U.S. and is available by prescription nationwide.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics' lead product VASCAZEN^® is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.

Disclosure Notice

The information contained in this document is as of April 30, 2013. This
press release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast", "intend",
"plan", "believe", "project", "potential", and similar expressions with
any discussion of future operating or financial performance or events.
In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to compete
with others who provide comparable products; risk that the Company's
products will not gain widespread market acceptance; risks relating to
the Company's ability to maintain its CSNX listing. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. The Company undertakes no obligation to publicly
update or revise any forward-looking statements contained in this
document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.